Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company has received the CE-IVD mark for its A...
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report fourth quarter and full year 2020 f...
Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Center SOUTH SAN FRANCISCO, Calif., Jan. 05, 2...
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the co...
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: FLDM shares. Investors, who purchased shares of Fluidigm Corporation (NASDAQ: FLDM) prior to February 2019 and continue to hold any of those...
Glenview Capital Management’s 13F portfolio value decreased from $3.63B to $3.19B this quarter. The number of positions increased from 43 to 45. They increased Myriad Genetics, while decreasing Quest Diagnostics, DaVita, and United Rentals during the quarter. The top three ...
Fluidigm is a life science company focused on cytometry and microfluidic solutions that has seen significant COVID tailwinds. Revenue are up nearly 50% YoY and profitability has dramatically improved. Valuation is compelling and I recommend a buy at these levels. For further...
Fluidigm ([[FLDM]] +2.5%) shares fluctuate in the early going, opening higher then turning lower before again moving higher, after India's Central Drugs Standard Control Organization licenses the import and commercial sale of the company's COVID-19 assay for testing.The CDSCO license was gran...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the Central Drugs Standard Control Organisation (CDSCO)...
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that the company’s management will participate in the Pipe...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report second quarter 2024 financial results on Wednesday, July 31, 2024, after the close of the...
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high-throughput large and small molecule screening and characteriza...
Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 Delivered pro forma combined revenue of $46.2 million, gross margin of 49.2%, non-GAAP gross margin of 56.3%, operating expense reduction of app...